ONCY Stock Oncolytics Biotech (ONCY, $1.03) soared +156.86% in three months, becoming one of the top quarterly gainers among penny stocks

GET DAILY SIGNALS

Get AI intraday signals

ONCY - Oncolytics Biotech

Loading...

Price: $1.03

Daily change: +$0.0412 (+4.17%)

Daily volume: 646.6K

3-month price change: +$0.629 (+156.86%)

Capitalization: $103.4M

Industry: Biotechnology

ONCY sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ONCY moved above the 200-day moving average on August 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 15, 2025. You may want to consider a long position or call options on ONCY as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ONCY just turned positive on August 21, 2025. Looking at past instances where ONCY's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

ONCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 100 cases where ONCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 52 cases where ONCY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ONCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.474) is normal, around the industry mean (19.605). P/E Ratio (0.000) is within average values for comparable stocks, (54.592). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.646). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (305.338).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.